Eman Hazimi
Gerontology · Taylor, MINPI 1811422413
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$996
- AbbVie$830
- Novo Nordisk$451
- Pfizer$443
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$278
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,153 |
| GSK | 43 | $996 |
| AbbVie | 53 | $830 |
| Novo Nordisk | 27 | $451 |
| Pfizer | 22 | $443 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $278 |
| Lilly USA, LLC | 14 | $220 |
| Exact Sciences | 10 | $214 |
| Eisai Inc. | 9 | $147 |
| UCB, Inc. | 7 | $113 |
| Xeris Pharmaceuticals, Inc. | 4 | $99 |
| Novartis | 5 | $86 |
| Amarin Pharma, Inc. | 5 | $73 |
| Merck | 4 | $68 |
| Amgen | 3 | $64 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Lundbeck LLC | 2 | $43 |
| Dexcom, Inc. | 3 | $41 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Tolmar, Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Evoke Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$500
How this compares
$5,663 in reported general payments places this provider in the 90th percentile of 279 gerontology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $31,069 |
| EliquisApixaban | 35 | $26,392 |
| OzempicSemaglutide | 20 | $19,524 |
| LinzessLinaclotide | 12 | $11,039 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 125 | $4,283 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 209 | $2,773 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,401 |
| Gabapentin | 94 | $1,112 |
| Diclofenac Sodium | 29 | $1,046 |
| Atorvastatin Calcium | 93 | $707 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 65 | $631 |
| Pregabalin | 15 | $616 |
| Celecoxib | 11 | $536 |
| Simvastatin | 62 | $520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $996 | $31,06944 claims |
| PfizerEliquis | $443 | $26,39235 claims |
| Novo NordiskOzempic | $451 | $19,52420 claims |
| AbbVieLinzess | $830 | $11,03912 claims |
| AstraZenecaBreztri Aerosphere | $1,153 | $8,97313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 gerontology providers in Michigan.
Other gerontology in Taylor
- Gwendolyn WrightGrand Blanc$47K
- Matthew AmanRochester Hills$21K
- Sarah ArnkoffWest Bloomfield$18K
- Deborah GriffinPetoskey$11K
- Angela EmbreeGrand Rapids$10K
- Bethany DalessandroWyandotte$10K
- Gabrielle NadeauJackson$10K
- Cynthera McNeillWest Bloomfield$9K
- Samantha BurgessGrand Rapids$9K
- Joanna HernandezWarren$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.